STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions. The sales took place on April 20, 2026 at prices generally between about $162 and $168 per ADS. Each ADS represents one ordinary share of the company. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.

Insights

Belite Bio’s CSO executed a small, pre-planned ADS sale under a Rule 10b5-1 plan.

The reporting person, Chief Scientific Officer Nathan L. Mata, sold a total of 1,000 American depositary shares of BELITE BIO, INC on April 20, 2026. All transactions were open-market sales in relatively small blocks at prices around the mid-$160s per ADS.

The filing specifies that these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, meaning the trades were pre-scheduled rather than opportunistic. There are no derivative exercises or tax-withholding events disclosed, and no remaining derivative positions are listed, so this reads as a routine, planned share sale with limited informational value for investors.

Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($164K)
Type Security Shares Price Value
Sale American depositary share 284 $162.7552 $46K
Sale American depositary share 524 $163.5193 $86K
Sale American depositary share 124 $164.4009 $20K
Sale American depositary share 40 $165.2935 $7K
Sale American depositary share 3 $166.905 $500.72
Sale American depositary share 16 $167.165 $3K
Sale American depositary share 9 $168.35 $2K
Holdings After Transaction: American depositary share — 13,382 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $162.01 to $162.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $163.01 to $163.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $164.0125 to $164.90. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $165.03 to $165.66. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $167.06 to $167.26. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $168.21 to $168.425. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
ADS sold 1,000 ADS Total American depositary shares sold on April 20, 2026
Price range (low) $162.01 per ADS Lower end of weighted-average sale price range in one trade group
Price range (high) $168.425 per ADS Upper end of weighted-average sale price range in one trade group
Representative sale price $163.5193 per ADS Weighted average price for a 524-share sale block
ADS-to-share ratio 1 ADS = 1 ordinary share Each American depositary share represents one ordinary share of the issuer
Rule 10b5-1 adoption date December 10, 2025 Date the pre-arranged trading plan governing these sales was adopted
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from $162.01 to $162.97."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.
(Last)(First)(Middle)
7708 MARKER ROAD
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)04/20/2026S(2)284D$162.7552(3)13,382D
American depositary share(1)04/20/2026S(2)524D$163.5193(4)12,858D
American depositary share(1)04/20/2026S(2)124D$164.4009(5)12,734D
American depositary share(1)04/20/2026S(2)40D$165.2935(6)12,694D
American depositary share(1)04/20/2026S(2)3D$166.90512,691D
American depositary share(1)04/20/2026S(2)16D$167.165(7)12,675D
American depositary share(1)04/20/2026S(2)9D$168.35(8)12,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $162.01 to $162.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $163.01 to $163.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $164.0125 to $164.90. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $165.03 to $165.66. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $167.06 to $167.26. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
8. Represents the weighted average price of shares sold at prices that ranged from $168.21 to $168.425. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata04/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Belite Bio (BLTE) disclose about Nathan L. Mata’s recent share transactions?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares in the company. The open‑market sales occurred on April 20, 2026, and were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted in December 2025.

How many Belite Bio (BLTE) ADS did the CSO sell and at what prices?

The CSO sold 1,000 American depositary shares in total. Individual trades were executed in small blocks, with weighted average prices generally between about $162 and $168 per ADS, reflecting multiple transactions across that price range on the same trading date.

What is the significance of the Rule 10b5-1 plan in Belite Bio’s (BLTE) Form 4?

The Form 4 states the sales were made under a Rule 10b5‑1 trading plan adopted on December 10, 2025. Such plans pre‑schedule trades, indicating these transactions were arranged in advance rather than being discretionary responses to short‑term market movements or company developments.

What security did Nathan L. Mata trade in the Belite Bio (BLTE) Form 4 filing?

He traded American depositary shares of Belite Bio. The filing clarifies that each ADS represents one ordinary share of the issuer, with a par value of US$0.0001 per share, giving investors clarity on the underlying equity represented by the deposited securities.

Were there any option exercises or derivative transactions in this Belite Bio (BLTE) Form 4?

No derivative transactions were reported. The filing shows only non‑derivative, open‑market sales of American depositary shares and indicates a derivative transaction count of zero, with no option exercises, conversions, or tax‑withholding share dispositions disclosed for this reporting period.